rs587783772
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM2PM5PP3_StrongPP5_Very_Strong
The NM_000252.3(MTM1):c.1262G>A(p.Arg421Gln) variant causes a missense, splice region change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000915 in 1,092,415 control chromosomes in the GnomAD database, with no homozygous occurrence. There are no hemizygote samples in GnomAD. In-silico tool predicts a pathogenic outcome for this variant. 2/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R421L) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000252.3 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
MTM1 | NM_000252.3 | c.1262G>A | p.Arg421Gln | missense_variant, splice_region_variant | 12/15 | ENST00000370396.7 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
MTM1 | ENST00000370396.7 | c.1262G>A | p.Arg421Gln | missense_variant, splice_region_variant | 12/15 | 1 | NM_000252.3 | P1 |
Frequencies
GnomAD3 genomes Cov.: 23
GnomAD4 exome AF: 9.15e-7 AC: 1AN: 1092415Hom.: 0 Cov.: 28 AF XY: 0.00 AC XY: 0AN XY: 358167
GnomAD4 genome Cov.: 23
ClinVar
Submissions by phenotype
Severe X-linked myotubular myopathy Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Dec 31, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | 3billion | Mar 22, 2022 | Same or different nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000158914, PMID:9285787). The variant has been observed in multiple (>3) similarly affected unrelated individuals (PMID: 22520358, 9285787, 9305655, 11793470). A different missense change at the same codon has been reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000599006, PMID:26338224). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.974>=0.6, 3CNET: 0.994>=0.75). It is not observed in the gnomAD v2.1.1 dataset. Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. - |
Pathogenic, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Feb 08, 2013 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 15, 2020 | For these reasons, this variant has been classified as Pathogenic. This variant has been reported to affect MTM1 protein function (PMID: 23071445, 12646134, 23917616, 21135508, 17973976). This variant has been observed in individuals with myotubular myopathy (PMID: 22520358, 9285787, 9305655, 11793470, 10790201). ClinVar contains an entry for this variant (Variation ID: 158914). This variant is not present in population databases (rs587783772, ExAC no frequency). This sequence change replaces arginine with glutamine at codon 421 of the MTM1 protein (p.Arg421Gln). The arginine residue is highly conserved and there is a small physicochemical difference between arginine and glutamine. - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Sep 07, 2017 | The p.R421Q substitution has been reported in multiple individuals and has been reported previously as amaternally inherited variant in an individual with severe myotubular myopathy, and supportive histologicalfindings on muscle biopsy (Koga et al., 2012). Crystallography has shown that R421 is located within thephosphatase domain and functional studies showed that p.R421Q eliminated phosphatase activity (Goryunovet al., 2008). This substitution occurs at a position that is conserved across species, and multiple variants have been reported in nearby residues in association with myotubular myopathy (Stenson et al., 2009).Therefore, p.R421Q is considered a pathogenic variant. - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen | Feb 01, 2021 | - - |
Spastic paraplegia Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Blueprint Genetics | - | - - |
Congenital myopathy with fiber type disproportion Pathogenic:1
Pathogenic, criteria provided, single submitter | research | Muscle and Diseases Team, Institut de Génétique et Biologie Moléculaire et Cellulaire | Mar 01, 2024 | PS1+PS2+PM1+PM2+PP2+PP3+PP4+PP5 - |
Centronuclear myopathy Pathogenic:1
Pathogenic, criteria provided, single submitter | research | Muscle and Diseases Team, Institut de Génétique et Biologie Moléculaire et Cellulaire | Mar 01, 2024 | PS1+PS2+PM1+PM2+PP2+PP3+PP4+PP5 - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at